BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon.

Stanchina, Michele; McKinnell, Zoe; Park, Jae H; Stein, Eytan M; Cai, Sheng F; Taylor, Justin

Stanchina, Michele; McKinnell, Zoe; Park, Jae H; Stein, Eytan M; Cai, Sheng F; Taylor, Justin.

Afiliación

Stanchina M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
McKinnell Z; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Park JH; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Stein EM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cai SF; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Taylor J; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Leuk Res Rep ; 14: 100211, 2020.

Article en En | MEDLINE | ID: mdl-32637309

Palabras clave

Bcr-abl; Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Ponatinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Leuk Res Rep Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google